Key result
A 14-day course of ganciclovir reduced the incidence of CMV disease compared to CMV immunoglobulin in CMV-seropositive heart transplant recipients receiving OKT3.
Why the study?
Does ganciclovir reduce CMV disease compared to CMV immunoglobulin in CMV-seropositive heart transplant recipients treated with OKT3?
RCT (n=31)
Randomized
No
Does ganciclovir reduce CMV disease compared to CMV immunoglobulin in CMV-seropositive heart transplant recipients treated with OKT3?
A 14-day course of ganciclovir is more effective than CMV immunoglobulin for preventing CMV disease in CMV-seropositive heart transplant recipients receiving OKT3 induction therapy.
Answers are grounded in this paper and cite their sources.
Supports ganciclovir over CMV immunoglobulin for prophylaxis in OKT3-treated heart transplant recipients; confirms RCT superiority in reducing CMV disease.
We compared the efficacy of ganciclovir versus that of cytomegalovirus (CMV) immunoglobulin for the prevention of CMV disease in 31 CMV-seropositive heart transplant recipients who had received early immunoprophylaxis with OKT3 monoclonal antibodies. The incidence of CMV disease and visceral involvement was much higher in the CMV immunoglobulin group than in the ganciclovir group (40 versus 6%, respectively; P = 0.03). No adverse effects were found in the CMV immunoglobulin group, but 19% of the patients in the ganciclovir group developed mild leukopenia or a mild increase in their serum creatinine levels.
No takes yet. Share an insight, caveat, or question.
Aguado et al. (1995) conducted an RCT in Cytomegalovirus (CMV) infection in heart transplant recipients (n=31). Ganciclovir vs. CMV immunoglobulin was evaluated on Development of CMV disease (p=0.03). A 14-day course of ganciclovir reduced the incidence of CMV disease compared to CMV immunoglobulin in CMV-seropositive heart transplant recipients receiving OKT3.
Synapse has enriched 10 related papers. Consider them for comparative context: